Mu dheidhinn aillse / làimhseachadh / drogaichean / craiceann

Bho love.co
Leum gu seòladh Leum airson sgrùdadh
Cànanan eile:
Sasannach

Drogaichean air an aontachadh airson aillse craicinn

Tha an duilleag seo a ’liostadh dhrogaichean aillse a chaidh aontachadh leis an Rianachd Bidhe is Drugaichean (FDA) airson aillse craiceann, a’ toirt a-steach drogaichean airson carcinoma cealla basal, melanoma, agus carcinoma cealla merkel. Tha an liosta a ’toirt a-steach ainmean gnèitheach agus ainmean branda. Tha na h-ainmean dhrogaichean a ’ceangal ri geàrr-chunntasan Fiosrachadh Drogaichean aillse NCI. Is dòcha gu bheil drogaichean air an cleachdadh ann an aillse craiceann nach eil air an liostadh an seo.

AIR AN DUILLEAG SEO

  • Drogaichean ceadaichte airson carcinoma cealla basal
  • Drogaichean air an aontachadh airson carcinoma cealla squamous cealla
  • Drogaichean ceadaichte airson melanoma
  • Drogaichean ceadaichte airson carcinoma cealla Merkel

Drogaichean ceadaichte airson carcinoma cealla basal

Aldara (Imiquimod)

Efudex (Fluorouracil - Cuspaireil)

Erivedge (Vismodegib)

5-FU (Fluorouracil - Cuspaireil)

Fluorouracil - Cuspaireil

Imiquimod

Odomzo (Sonidegib)

Sonidegib

Vismodegib

Drogaichean air an aontachadh airson carcinoma cealla squamous cealla

Cemiplimab-rwlc

Libtayo (Cemiplimab-rwlc)

Drogaichean ceadaichte airson melanoma

Aldesleukin

Cobimetinib

Cotellic (Cobimetinib)

Dabrafenib

Dacarbazine

DTIC-Dome (Dacarbazine)

IL-2 (Aldesleukin)

Imlygic (Talimogene Laherparepvec)

Interleukin-2 (Aldesleukin)

Intron A (Interferon Interferon Alfa-2b)

Ipilimumab

Keytruda (Pembrolizumab)

Mekinist (Trametinib)

Nivolumab

Opdivo (Nivolumab)

Peginterferon Alfa-2b

Pembrolizumab

Proleukin (Aldesleukin)

Interferon ath-leasachail Alfa-2b

Sylatron (Peginterferon Alfa-2b)

Tafinlar (Dabrafenib)

Talimogene Laherparepvec

Trametinib

Vemurafenib

Yervoy (Ipilimumab)

Zelboraf (Vemurafenib)

Drogaichean ceadaichte airson carcinoma cealla Merkel

Avelumab

Bavencio (Avelumab)

Keytruda (Pembrolizumab)

Pembrolizumab